Unit Trusts


ARK Genomic Healthcare and Biotech Portfolio, 4Q 2015

Portfolio Holdings

Illumina, Inc. ILMNHealth Care6.03 %
Foundation Medicine, Inc. FMIHealth Care5.28 %
Monsanto CompanyMONMaterials4.99 %
athenahealth, Inc. ATHNHealth Care4.94 %
Thermo Fisher Scientific, Inc.TMOHealth Care4.54 %
Medidata Solutions, Inc. MDSOHealth Care4.54 %
Cepheid, Inc. CPHDHealth Care4.51 %
Regeneron Pharmaceuticals, Inc. REGNHealth Care4.50 %
Alnylam Pharmaceuticals, Inc.ALNYHealth Care4.06 %
NVIDIA CorporationNVDAInformation Technology4.04 %
Novartis AGNVSHealth Care3.51 %
Incyte Corporation INCYHealth Care3.04 %
CerUnited States Corporation CERSHealth Care3.00 %
Bristol-Myers Squibb CompanyBMYHealth Care2.98 %
Biogen Inc. BIIBHealth Care2.97 %
Celgene Corporation CELGHealth Care2.47 %
Mettler-Toledo International Inc. MTDHealth Care2.05 %
Amazon.com, Inc. AMZNConsumer Discretionary2.04 %
Laboratory Corporation of America Holdings LHHealth Care2.01 %
Invitae Corporation NVTAHealth Care2.01 %
Hortonworks Inc. HDPInformation Technology2.01 %
Veracyte, Inc. VCYTHealth Care2.01 %
Roche Holding AGRHHBYHealth Care2.00 %
BioMarin Pharmaceutical Inc. BMRNHealth Care2.00 %
Ionis Pharmaceuticals, Inc.IONSHealth Care1.99 %
Compugen Ltd. CGENHealth Care1.99 %
Gilead Sciences, Inc. GILDHealth Care1.97 %
Bayer AG BAYRYHealth Care1.54 %
Bluebird Bio, Inc. BLUEHealth Care1.48 %
Johnson & JohnsonJNJHealth Care1.48 %
Agios Pharmaceuticals, Inc. AGIOHealth Care1.04 %
Novozymes A/S NVZMYMaterials1.02 %
Five Prime Therapeutics, Inc. FPRXHealth Care1.02 %
NewLink Genetics Corporation NLNKHealth Care1.01 %
Intrexon CorporationXONHealth Care1.00 %
UNIQURE N.V. QUREHealth Care0.99 %
Kite Pharma, Inc. KITEHealth Care0.97 %
Seres Therapeutics, Inc. MCRBHealth Care0.97 %

Data used for the Portfolio Holdings and Portfolio Allocation Characteristics is from Bloomberg Finance L.P. Portfolio holdings are provided for informational purposes only and should not be deemed as a recommendation to buy or sell individual securities. Portfolio Holdings and Portfolio Allocation Characteristics are as of deposit day and are subject to change and may vary thereafter.

The style and capitalization characteristics are designed to help investors understand how they fit into an overall investment plan. Value, blend and growth are types of investment styles. Growth Investing generally seeks stocks that offer the potential for greater-than-average earnings growth, and may entail greater risk than value or blend investing. Value investing generally seeks stocks that may be sound investments but are temporarily out of favor in the marketplace, and may entail less risk than growth investing. A blend investment combines the two styles. Market capitalization is determined by the following criteria: Large Cap: Greater than $10 billion, Mid Cap: $2 billion-$10 billion, Small Cap: $250 million-$2 billion Micro Cap: Below $250 million.

This material is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy or sell securities, and is not provided in a fiduciary capacity. The information provided does not take into account the specific objectives or circumstances of any particular investor, or suggest any specific course of action. Investment decisions should be made based on an investor’s objectives and circumstances and in consultation with his or her advisors.

Risk Considerations
There is no assurance that a unit investment trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. This trust is unmanaged. You can lose money investing in this trust.
Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer’s board of directors and the amount of any issuer’s dividend may vary from time to time.
A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors.
This trust is concentrated in the healthcare sector. There are certain risks specific to the healthcare companies such as governmental regulation and the risk that a product may never come to pass.
This trust is concentrated in securities of biotechnology companies. Biotechnology companies are subject to government regulation and their valuation can often be based on the potential or actual performance of a limited number of products and can be greatly affected if such products proves to be unsafe, ineffective, or unprofitable.
The trust invests in the securities of pharmaceutical companies. Companies in the pharmaceutical industry can be significantly affected by government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition.
Investing in foreign securities involves certain risks not typically associated with investing solely in the United States. This may magnify volatility due to changes in foreign exchange rates, the political and economic uncertainties in foreign countries, U.S. or foreign tax treatment, and the potential lack of liquidity, government supervision and regulation.
Stocks of small and mid-cap companies are often more volatile than those of larger companies as a result of several factors such as limited trading volumes, products or financial resources, management inexperience and less publicly available information.
Although this trust’s life is approximately 15 months, this strategy should be considered as part of a long-term investment strategy and investors should consider their ability to pursue investing in successive portfolios at the applicable sales charge, if available. There may be tax consequences associated with an investment from one series to the next unless units are purchased in an IRA or other qualified tax-deferred account. Investors should consult their tax advisor or attorney to determine tax consequences associated with an investment from one portfolio to the next.
Incapital Unit Trust, Series 112, is a unit investment trust that consists of the ARK Genomic, Healthcare and Biotech Portfolio, 4Q 2015. Nuveen Securities, LLC serves as the Trust’s sponsor and Nuveen Fund Advisors, LLC serves as the Trust’s evaluator and supervisor.
ARK Investment Management (“ARK”) provides the Trust with portfolio consulting services. ARK Investment Management is not affiliated with Nuveen, LLC. The Trust is distributed by Nuveen Securities, LLC, a subsidiary of Nuveen, LLC. All marketing materials have been prepared by Nuveen.

Trust Summary

Trust NameARK Genomic Healthcare and Biotech Portfolio, 4Q 2015
Series Name4Q 2015
Trust SymbolAHB4Q15
Nasdaq SymbolINAHAX
Trust StatusTerminated
Initial Offer Date12/22/2015
Termination Date03/21/2017
First Income Record Date12/31/2015
Distibution FrequencySemi-annually
Tax StructureRIC
Liquidation Price1$9.7314
Cash CUSIP45332K109
Reinvest CUSIP45332K117
Fee Cash CUSIP45332K125
Fee Reinvest CUSIP45332K133

1. Represents the value per unit that a unitholder would receive if the unitholder redeemed or sold units. This price is equal to the net asset value per unit plus any remaining organization costs and creation & development fee. This price reflects any remaining non-contingent deferred sales charges payable in connection with a liquidation of units.

Not registered?

Register for access to investment team commentary, detailed portfolio information, and other advisor resources. For instant access, register now.

Your Contacts

Our goal is to deliver lasting value to our clients. For assistance, please call or email our advisor service team or contact your personal Nuveen Service Team.

Log in to nuveen.com to access your personal Nuveen Service Team.

Financial Advisors


Registered Investment Advisors


Account Access

For more information on Mutual Fund Vision, FAN Mail, or accessing client accounts, please visit our advisor account access page.

Advisor Access

Investor Access